Transdermal buprenorphine
by
Evans H, Easthope S.
Adis International Limited,
Auckland, New Zealand.
Drugs. 2003;63(19):1999-2010


ABSTRACT

Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. black triangle At least satisfactory analgesia with minimal requirement for rescue medication (50% of patients treated with transdermal buprenorphine, in two trials. Furthermore, despite the availability of rescue medication to all patients, those receiving transdermal buprenorphine tended to experience greater pain relief, reduced pain intensity and longer pain-free sleep. black triangle Transdermal buprenorphine was generally well tolerated. Systemic adverse events were typical of opioid treatment or were attributable to the underlying disease.
HS-599
Methadone
Sugar junkies
Endomorphins
Norbuprenorphine
LAAM v methadone
Subutex and Suboxone
Opioids and depression
Buprenorphine : structure
Buprenorphine and reward
Buprenorphine and naltrexone
Buprenorphine and the receptors
Buprenorphine as an antidepressant
Buprenorphine: the standard wisdom
Buprenorphine : behavioral pharmacology
Buprenorphine versus buprenorphine/nalaxone
Buprenorphine (Buprenex, Temgesic) versus placebo or methadone


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family